← Back to catalogue
Research draft

Chagas disease

vr.tr.chagas-disease · XCT.STA

Enable an agent to recognise Chagas disease, assess infection certainty and clinical state, and identify evidence-supported diagnostic, care and transmission-prevention actions.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

recalled by Codex without web access - no source was read

Researched by: Codex

Purpose and description

Enable an agent to recognise Chagas disease, assess infection certainty and clinical state, and identify evidence-supported diagnostic, care and transmission-prevention actions.

Chagas disease is a parasitic infection caused by Trypanosoma cruzi that can persist lifelong and cause chronic cardiac, gastrointestinal or other organ damage after an acute phase that is often mild or unrecognized.

It can be Identify missing evidence needed to resolve suspected T. cruzi infection.; Check whether the diagnostic pathway fits the disease phase and testing purpose.; Assemble a dated assessment of organ involvement and possible reactivation.; Support clinician review of antiparasitic eligibility and monitoring needs.; Identify congenital, donation-related or shared-exposure investigation pathways.; Compare disease assertions and population estimates only when definitions and versions align..

Distinguishing features

Require evidence of Trypanosoma cruzi infection; an insect bite or residence in an endemic area establishes exposure plausibility, not disease confirmation. [CDC diagnosis guidance](https://www.cdc.gov/chagas/hcp/diagnosis-testing/index.html)

Distinguish the infection from its organ manifestations: absence of symptoms does not exclude Chagas disease. [WHO overview](https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis))

For chronic infection, check for concordant serology using different antigens; a single reactive screening assay does not establish a clinical diagnosis. [CDC diagnosis guidance](https://www.cdc.gov/chagas/hcp/diagnosis-testing/index.html)

Check the organism attribution before accepting an unspecified trypanosomiasis label: this entry covers T. cruzi infection. [CDC case definition](https://ndc.services.cdc.gov/case-definitions/chagas-disease/)

Scope

+ Evidence attributing infection to Trypanosoma cruzi

+ Acute and chronic phases, with reactivation assessed separately

+ Cardiac, digestive, neurological and mixed manifestations

+ Phase-appropriate diagnostic evidence and versioned case definitions

+ Antiparasitic treatment eligibility, response and longitudinal monitoring

+ Transmission routes, exposed populations and prevention implications

- The patient's complete medical and demographic record

- The taxonomy and full life cycle of Trypanosoma cruzi

- Triatomine species inventories and vector-control operations

- Clinical encounters, prescriptions and laboratory workflow execution

- Independent models of cardiomyopathy, arrhythmia or digestive disorders

- African trypanosomiasis and other parasitic diseases

Characteristics

Infection assertion
Suspected, confirmed, unresolved, excluded under named criteria; assessment date required Separates exposure, screening results and established infection.
Disease phase
Acute, chronic, uncertain; onset estimate and assignment criteria Determines how diagnostic evidence and treatment decisions should be interpreted.
Reactivation assessment
Not assessed, no evidence, suspected, confirmed; dated evidence Keeps renewed parasite activity distinct from ordinary chronic progression.
Organ involvement
None detected after specified assessment, cardiac, digestive, neurological, mixed, incompletely assessed Prevents missing investigations from being interpreted as absence of organ disease.
Diagnostic evidence
Linked specimens, assay identities, results, dates, laboratory reports and interpretation Makes confirmation and discordance reviewable.
Acquisition route
Vector-associated, congenital, oral, transfusion, transplantation, laboratory exposure, unknown; suspected or supported Connects disease recognition to route-specific investigation.
Cardiac functional assessment
Left ventricular ejection fraction in percent, with method and date; linked rhythm and conduction findings Supports assessment of cardiac involvement without reducing it to one measurement.
Antiparasitic treatment status
Not assessed, considered, deferred, underway, completed, interrupted; rationale and dates Separates treatment delivery from evidence of treatment success.
Classification mapping
Verified ICD-10, ICD-11 or SNOMED CT concept, release, jurisdiction and mapping scope Prevents unversioned codes from silently changing the meaning of a disease assertion.
Population prevalence
Percent or cases per stated population denominator, with geography, observation year, method and uncertainty Makes estimates comparable without treating screened samples as whole populations.

Also called

Chagas cardiomyopathy

Where this came from

wikidata · CC0 1.0

Source repository Registry entry point

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 7 bundles · 13 layers · 21 findings · 38 questions.

Infection identity and classification Establish what the Chagas disease assertion means and how it is represented.

Exposure, infection, organ disease and a coded encounter can otherwise be conflated.

Etiological boundary

Anchor this entry to the causal infection.

Trypanosoma cruzi attribution

Record the evidence supporting T. cruzi attribution and its uncertainty.

  1. What evidence attributes this condition to T. cruzi? provenance
  2. Does the record describe exposure, established infection or an attributed complication? boundary

Versioned disease assertions

Preserve the purpose and authority of diagnostic and classification labels.

Clinical and surveillance meaning

Surveillance classification must retain its separate purpose from clinical diagnosis. [CDC 2025 case definition](https://ndc.services.cdc.gov/case-definitions/chagas-disease/)

  1. Which issuing body, document version and jurisdiction govern this assertion? provenance
  2. Is the label a clinical diagnosis, surveillance classification or administrative code? boundary
  3. Which verified ICD or SNOMED release represents its phase and manifestations? definition
Acquisition and exposed populations Represent plausible acquisition and the population context of infection.

Chagas investigation must accommodate vector and non-vector transmission.

Transmission evidence

Separate route hypotheses from demonstrated links.

Route and exposure window

Consider vector-associated contamination, congenital, oral, transfusion, transplantation and laboratory routes. [WHO transmission overview](https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis))

  1. Which route is supported, and what exposure dates or locations constrain it? provenance
  2. What distinguishes a demonstrated transmission link from a plausible exposure? boundary

Population and geography

Keep acquisition history separate from present residence and population estimates.

Denominator and acquisition context

Attach population, time and ascertainment details to burden estimates.

  1. What residence, birth, maternal or travel history supports the acquisition assessment? provenance
  2. What population, observation year, denominator and testing strategy produced the prevalence estimate? measurement
Phase-appropriate confirmation Organise laboratory evidence around the clinical context and testing purpose.

Acute and chronic infection require different approaches to confirmation.

Parasite detection context

Capture direct detection evidence alongside timing and host context.

Acute and reactivation testing

Acute infection can be diagnosed by blood microscopy; interpretation must retain phase and specimen context. [CDC diagnosis guidance](https://www.cdc.gov/chagas/hcp/diagnosis-testing/index.html)

  1. Which direct or molecular test was performed, on what specimen and at what time? measurement
  2. Which protocol governs interpretation in acute, congenital or suspected reactivated infection? provenance

Chronic serological confirmation

Assess independent serological evidence and unresolved discordance.

Assay concordance and purpose

Record the assays supporting chronic diagnosis and distinguish donor screening from clinical confirmation. [CDC testing protocol](https://www.cdc.gov/chagas/hcp/diagnosis-testing/index.html)

  1. Which assays using different antigens support the chronic infection assertion? measurement
  2. What further testing does the applicable algorithm require for discordant results? action
  3. Was testing intended for donor screening or clinical diagnosis? boundary
Clinical course and organ involvement Represent disease evolution, assessed manifestations and reactivation.

Infection duration, symptoms and organ injury are separate dimensions.

Phase and reactivation

Track phase assignments and evidence of renewed activity.

Dated course assessment

Record acute or chronic phase and assess reactivation in the context of immunosuppression. [WHO disease course](https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis))

  1. What evidence and estimated infection timing support the assigned phase? provenance
  2. What findings support suspected reactivation rather than chronic organ progression? boundary

Manifestation attribution

Describe organ findings and the evidence linking them to Chagas disease.

Cardiac and digestive assessment

Evaluate cardiac conduction and structural findings alongside digestive megasyndromes. [CDC clinical care](https://www.cdc.gov/chagas/hcp/clinical-care/index.html)

  1. Which dated cardiac and digestive investigations establish involvement and severity? measurement
  2. Which competing causes were assessed before attributing these abnormalities to Chagas disease? boundary

Unassessed and neurological involvement

Retain neurological findings and assessment gaps without defaulting to an asymptomatic classification.

  1. Which neurological findings require specialist attribution or investigation? action
  2. Which required assessments support an indeterminate chronic form, and which remain incomplete? definition
Treatment and response Support treatment review and separate therapeutic aims from observed outcomes.

Parasite-directed treatment and management of established damage require distinct judgments.

Antiparasitic decision

Record the basis for treatment selection or deferral.

Eligibility and regimen authority

Benznidazole and nifurtimox are antiparasitic options; eligibility depends on clinical context and applicable guidance. [CDC treatment guidance](https://www.cdc.gov/chagas/hcp/clinical-care/index.html)

  1. How do age, phase, pregnancy or lactation, organ function and cardiac severity affect the decision? action
  2. Which guideline and local prescribing authority support the selected regimen or deferral? provenance

Response and continuing care

Distinguish completion, tolerability, infection response and organ outcomes.

Separate treatment endpoints

Treatment completion is not a cure criterion, and established organ pathology requires separate follow-up. [CDC care precautions](https://www.cdc.gov/chagas/hcp/clinical-care/index.html)

  1. What treatment exposure, interruptions and adverse effects were documented? measurement
  2. Which tests, observation period and criteria support a response or cure assertion? definition
  3. What organ-specific care remains necessary regardless of antiparasitic response? action
Congenital and transmission prevention Translate confirmed or suspected infection into linked prevention assessments.

Detection can reveal preventable transmission and additional people needing evaluation.

Maternal and infant linkage

Connect maternal infection evidence to infant and sibling evaluation.

Congenital exposure resolution

Record infant follow-up and family screening implications of maternal infection. [WHO prevention guidance](https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis))

  1. What maternal evidence establishes congenital exposure risk? provenance
  2. Which age-specific testing and follow-up protocol resolves the infant's infection status? action
  3. Which siblings require evaluation under the applicable guidance? action

Donation and shared exposure

Link disease evidence to blood, transplant and exposure investigations.

Route-specific prevention review

Identify relevant prevention pathways while retaining the authority responsible for each decision.

  1. Does the evidence require blood-bank, transplant-service or shared-exposure review? action
  2. Which current jurisdictional rules govern notification, donation eligibility and investigation? provenance
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.

A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.

Reported evidence

Findings from the breadth pass, kept separate from the structural claims.

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

  • This is recall-based information; no sources were consulted.
  • Verify current PAHO diagnostic guidance, congenital testing algorithms and the applicable ICD or SNOMED CT edition before operational use.
  • Prevalence estimates require a specified population and year; none are supplied here.
  1. Which of these check these first hold for the sense of Chagas disease this model covers, and on what evidence? provenance

Kinds and varieties

Recalled without web access and unsourced; every item is a lead to verify.

  • Acute Chagas disease
  • Chronic indeterminate Chagas disease
  • Chronic cardiac Chagas disease
  • Chronic digestive Chagas disease
  • Chronic mixed cardiac and digestive Chagas disease
  • Reactivated Chagas disease in immunosuppressed people
  1. Which of these kinds and varieties hold for the sense of Chagas disease this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

  • WHO ICD-10 - B57 - Chagas disease category; subcategories distinguish acute and chronic disease and organ involvement. Record the applicable national modification and revision.
  • SNOMED CT - Numeric concept identifier - The exact concept identifier and edition require verification.
  1. Which of these identifiers and schemes hold for the sense of Chagas disease this model covers, and on what evidence? provenance

Standards and regulation

Recalled without web access and unsourced; every item is a lead to verify.

  • Pan American Health Organization guidelines for the diagnosis and treatment of Chagas disease.
  • World Health Organization International Classification of Diseases, ICD-10 category B57.
  1. Which of these standards and regulation hold for the sense of Chagas disease this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

  • Acute and congenital infection assessment uses direct parasite detection or molecular methods according to clinical context and age.
  • Chronic infection diagnosis generally requires two serological tests using different antigen preparations or methods, with further testing for discordant results.
  • Evaluation of confirmed infection includes assessment for cardiac involvement and, when indicated, digestive involvement.
  • Blood and organ donor screening helps prevent transmission.
  • Benznidazole and nifurtimox are used for antiparasitic treatment; treatment decisions depend on disease phase, age and clinical circumstances.
  1. Which of these real-world use hold for the sense of Chagas disease this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

  • An initially silent infection can remain undiagnosed for decades before organ damage becomes apparent.
  • Cardiac involvement can cause conduction abnormalities, serious arrhythmias, heart failure, thromboembolism and sudden death.
  • Digestive involvement can cause megaesophagus or megacolon, with swallowing difficulties or severe constipation.
  • Immunosuppression can permit reactivation, including severe myocarditis or central nervous system disease.
  • Transmission can occur through infected triatomine feces, contaminated food or drink, congenital transmission, transfusion or transplantation; vector transmission is not ordinarily through the insect's saliva.
  1. Which of these failure modes and hazards hold for the sense of Chagas disease this model covers, and on what evidence? provenance

Regional variation

Recalled without web access and unsourced; every item is a lead to verify.

  • Vector-borne transmission is historically concentrated in continental Latin America; migration has made diagnosis and prevention relevant in other regions.
  • The relative importance of domestic vectors, sylvatic vectors and foodborne outbreaks varies geographically.
  • Digestive manifestations are reported more frequently in some southern South American populations than in many northern endemic populations.
  1. Which of these regional variation hold for the sense of Chagas disease this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

  • African trypanosomiasis - Caused by human-infective Trypanosoma brucei subspecies and transmitted by tsetse flies, whereas Chagas disease is caused by Trypanosoma cruzi.
  • Chagas cardiomyopathy - The cardiac manifestation of Chagas disease; infection can exist without cardiomyopathy.
  • Congenital Chagas disease - Chagas disease acquired through maternal transmission; this specifies the route of acquisition rather than a separate causative disease.
  • Positive Trypanosoma cruzi antibody test - A laboratory result rather than the disease itself; chronic infection ordinarily requires confirmation using an appropriate testing algorithm.
  1. Which of these neighbouring kinds and how to tell them apart hold for the sense of Chagas disease this model covers, and on what evidence? provenance

What the second pass must settle

  • Which exact ICD-10, ICD-11 and SNOMED CT concepts and releases map this entry and its manifestations without conflating infection, diagnosis and encounter?
  • Which issuing-body algorithms should govern discordant serology, congenital testing schedules and molecular evidence of reactivation in each intended jurisdiction?
  • Which operational criteria and staging systems should define indeterminate chronic infection and cardiac, digestive or neurological severity?
  • Which validated endpoints and follow-up periods justify cure or treatment-failure assertions in chronic infection?
  • Which population studies provide defensible prevalence estimates by geography, observation year and acquisition route, with denominators and uncertainty?
Draft as JSON